Fig. 8From: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s diseaseSimulations illustrating effects of varying crenezumab doses (mg/kg q4w) on plasma Aβ kinetics based on the developed PK/PD model. Note that total and free crenezumab concentrations overlap with each other. Abbreviations: Aβ beta-amyloid, PD pharmacodynamics, PK pharmacokinetics, q4w every 4 weeksBack to article page